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ABSTRACT
There are multiple different topical anesthetic
options available to minimize the pain
associated with cosmetic dermatologic
procedures. These options, either alone or in
combination, have diverse profiles for
effectiveness, ease of use, application time,
need for occlusion, and side effects. The
lidocaine/tetracaine cream (Pliaglis, Galderma
Laboratories, Texas, USA), one of the newer
combination options, offers effective pain
alleviation that has been evaluated in
numerous clinical trials. This combination
anesthetic is associated with a very favorable
profile because of its ease of use and mild side
effects compared to other topical local
anesthetics. An overview of available topical
local anesthetics will be provided with an
outline of clinical study characteristics and
results regarding the use of lidocaine/
tetracaine cream.
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procedures; Lidocaine; Pain; Pliaglis;
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INTRODUCTION
Due to the popularity of cosmetic procedures,
there is a growing need for topical anesthetics
that can be used in an outpatient setting for
various dermatological therapies. Injectable
anesthetics can be viewed as painful and, thus,
difficult to administer in patients who are afraid
of needles. One of the benefits of topical local
anesthetics is effective anesthesia for certain
procedures with little to no systemic exposure
to the agent. However, topical anesthetics are
often limited by the need for occlusive dressings
in order to enhance their epidermal penetration
[1, 2]. In addition, inadequate or non-uniform
placement of anesthesia over the skin area,
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messy application, and need for a lengthy
application period are other limitations of
topical anesthetics [1, 2]. Ideally, topical
anesthetics must be able to penetrate the
relatively impermeable barrier of the stratum
corneum and have minimal systemic
absorption [3, 4].
There are various forms of local anesthetics.
Each has a molecular structure that includes an
aromatic ring, an intermediate chain, and an
amine group. All local anesthetics are
lipophilic and soluble in water [5]. Lipophilia
permits diffusion of the anesthetic through
nerve cell membranes, and water solubility
allows preparation, storage, and administration
of the agent [5]. The intermediate chain
determines the division of anesthetics into
two classes: amide- or ester-containing [6].
Common amide anesthetics include lidocaine,
prilocaine, etidocaine, and bupivacaine [6].
Procaine, benzocaine, and tetracaine are
common ester anesthetics [6]. Amide
anesthetics are often preferred over ester
anesthetics because of the allergic reactions
associated with the ester class [6, 7]. Most
topical anesthetics consist of lidocaine,
prilocaine, tetracaine, or a combination of
them [8, 9]. All local anesthetics except
cocaine have vasodilatory effects [7]. An ideal
topical anesthetic agent would be easy to
apply, show high clinical effectiveness over a
short time period, exert its effect on intact skin
without systemic effects, and cause nominal
pain or discomfort during treatment with
minimal to no side effects [1, 3]. There have
been many different formulations developed to
meet these characteristics [3]. An overview of
available topical local anesthetics will be
provided with an outline of clinical study
characteristics and results regarding the use of
lidocaine/tetracaine cream for dermatologic
laser procedures.
METHODS
A literature search was conducted in MEDLINE
and EMBASE for articles published in English
pertaining to topical anesthetics. The search
terms included ‘‘Pliaglis,’’ ‘‘peel,’’ ‘‘lidocaine,’’
‘‘tetracaine,’’ ‘‘local,’’ ‘‘topical,’’ ‘‘laser,’’
‘‘dermatology,’’ and ‘‘anesthetics’’. Individual
articles identified as relevant and pertaining to
the scope of this review were identified and
summarized.
Current Treatments
Various topical anesthetics are available over-
the-counter or upon a physician’s prescription.
General anesthetics have evolved from ‘‘coca,’’
used by the Incas, to the use of cocaine. In the
late nineteenth century and early twentieth
century, the isolation and use of ester
anesthetics as topical agents came into
practice [5]. The high degree of allergic
reactions and severe side effects associated
with this class favored use of the amide class
over these first options. As a consequence,
several formulations contain lidocaine (the
most commonly used topical amide
anesthetic), but each one differs in
administration, length of duration, cost, and
concentration [6]. Many of the over-the-counter
topical anesthetics contain lidocaine (4 % or
5 %) as a monotherapy or in combination with
another topical anesthetic. Some examples of
these over-the-counter topical products include
LMX (Ferndale Laboratories, Ferndale, MI,
USA), Betacaine enhanced Gel 4 (Tiberius,
Inc., Tampa, FL, USA), and Topicaine 4 %
(ESBA Laboratories, Inc., Jupiter, FL, USA) [6].
Tetracaine (4 %) has also been formulated and
distributed as a monotherapy. It is more
lipophilic than lidocaine and accumulates in
the stratum corneum where it slowly diffuses,
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prolonging its duration and limiting systemic
uptake [10].
The most common topical anesthetic, and
often regarded as the gold standard by which
others are compared, is EMLA cream (Astra
Pharmaceuticals, Westborough, MA, USA) [6,
11]. EMLA cream is an emulsion in which the
oil phase is a eutectic mixture of 2.5 % lidocaine
and 2.5 % prilocaine [1]. Another common
topical lidocaine formulation, LMX, uses
liposomes as the delivery method for
improved penetration and for sustained release
of the anesthetic agent (4 % lidocaine) even
after the cream is removed from the skin [6, 11].
Both of these topical treatment options are
effective at relieving pain, but they require
lengthy application times and occlusion, and
may provide inadequate anesthesia at
peripheral skin margins [11, 12]. EMLA cream
has proven to have anesthetic efficacy in several
clinical trials involving such dermatologic
procedures as cryotherapy, pulsed dye laser
treatment, and debridement of leg ulcers [13–
16].
Lidocaine/tetracaine cream (Pliaglis,
Galderma Laboratories, Texas, USA) is the first
Food and Drug Administration (FDA)-approved
stable compounded mixture of 7 % lidocaine
and 7 % tetracaine cream [11]. Lidocaine/
tetracaine cream has the highest approved
concentrations of lidocaine and tetracaine that
has also proven to be safe and effective in
producing local dermal anesthesia for
dermatological procedures [12]. Its novel
vehicle functions as a self-occluding cream—
the product is applied as a cream that dries to a
pliable membrane upon exposure to air [6, 12].
This unique formulation allows for easy
application, removal, and access to areas
deemed difficult for other topical anesthetics.
The lidocaine/tetracaine cream was available on
the market for approximately a year and a half
before it was voluntarily removed due to
manufacturing issues unrelated to safety at a
third party contract manufacturer. It has
recently been made available again with
Galderma Laboratories responsible for its
manufacture.
Mode of Action
Local anesthetics function by preventing the
depolarization of nerve cells by the inhibition
of sodium channels and thereby blocking nerve
conduction [5, 6]. Myelinated A nerve fibers are
typically responsible for regulating pain and
temperature [5]. Sodium ion flux across the
nerve cell membrane allows for the
depolarization of the cell and the resultant
activation of the nerve. Epinephrine or
another adrenergic agonist is often added to
the local topical agent in order to prolong the
anesthetic effects by increasing vasoconstriction
and decreasing the rate of systemic absorption
[11]. Vasoconstriction increases the duration of
time the agent is in contact with the nerve
fibers; thus, prolonging the anesthetic effects
[11].
Dose, Administration, and Duration
Lidocaine/tetracaine cream is a topical local
anesthetic cream composed of equal parts of
lidocaine (7 %) and tetracaine (7 %) that forms a
pliable membrane on the skin when exposed to
air. It is indicated for use on intact skin in adults
to provide topical local analgesia for superficial
dermatological procedures. A flat-surfaced tool,
such as a metal spatula or tongue depressor, can
be used to apply a uniform thin (1 mm) layer of
the cream.
Lidocaine/tetracaine cream has been
demonstrated to be safe and effective with
minimal side effects [3]. The median duration
Pain Ther (2013) 2:11–19 13
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of analgesia in a clinical study of 40 subjects was
11 h. No differences in analgesic effect have
been seen for 30- and 60-min application
periods [17]. The systemic absorption of
lidocaine and tetracaine is directly related to
both the duration of application and the surface
area over which it is applied [17]. Application of
59 g of lidocaine/tetracaine cream over 400 cm2
for up to 120 min in adults produced peak
lidocaine concentrations of 220 ng/mL and
undetectable tetracaine plasma levels (\0.9 ng/
mL) [17]. The amount of lidocaine/tetracaine
cream to be used, measured in length by a ruler,
is determined by the size of the area to be
treated based on a chart found in the
prescribing information insert.
Most other prescribed topical anesthetics are
applied to the skin and occluded with plastic
wrap to enhance cutaneous absorption. The
occlusion and the duration of application
increase the cream’s penetration and efficacy
[18–20]. EMLA cream, similar to other topical
anesthetics, requires 40–60 min of application
under occlusion for adequate analgesic effect
[21]. Analgesia is achieved to a depth of 3 mm
after 60 min and a maximum depth of 5 mm
after 120 min of EMLA exposure [5]. As such,
EMLA has been shown to provide effective
anesthesia for several different procedures, but
requires occlusion and does not provide
adequate anesthesia at peripheral skin margins
[1, 13–16].
CLINICAL EVALUATION: EFFICACY
There have been numerous clinical studies that
evaluated the effectiveness of lidocaine/
tetracaine cream as an anesthetic agent. One
of the earliest trials evaluated its use for
cutaneous laser surgery compared to placebo
[2]. The blinded, randomized trial had three
protocols with different anesthetic application
times. In the first protocol, 30 subjects were
randomized to receive placebo or lidocaine/
tetracaine cream for 60 min. The subjects, the
investigators performing the laser surgery, and
an independent observer evaluated clinical
effectiveness. In the second and third
protocols, subjects (n = 15, each) were
randomized to receive placebo or lidocaine/
tetracaine cream for 20 or 30 min [2]. Subjects
that received the active drug had less pain
compared to those who received the placebo
[2]. The pain ratings on the visual analog scale
(VAS) were similar for the three end points [2].
In the total subject population, 9 % receiving
the active drug reported inadequate pain relief
compared to 66 % in the placebo group [2].
Similarly, the investigators rated 75 % of the
lidocaine/tetracaine cream subjects with no
pain and 25 % for the placebo group [2].
Similar results were obtained in two
randomized, double-blind, placebo-controlled
studies that evaluated anesthetic effect of
lidocaine/tetracaine cream for laser treatment
on the legs [1]. The first study followed 60
subjects where each subject served as his or her
own control receiving both lidocaine/tetracaine
cream and placebo. Application sites and
duration of application (30 or 60 min) were
randomly assigned. Thirty-minute application
times were determined to be inadequate, so
subsequent subjects were assigned to 60-min
application times [1]. The second study
evaluated 40 subjects using 60- and 90-min
application times for identical laser treatment
parameters [1]. Subjects evaluated anesthetic
efficacy based on a VAS scale, whereas
investigators and independent observers
evaluated efficacy on a separate pain scale.
Study 1 subjects in the active drug group had
statistically lower VAS scores compared to
placebo subjects (P = 0.046) [1]. Investigators
14 Pain Ther (2013) 2:11–19
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reported no pain in 50 % of active drug subjects
and in 33 % of placebo subjects. Study 2
subjects in the active drug group also had
statistically better VAS scores compared to the
placebo subjects for both time points (P = 0.01
and P\0.001) [1]. Lidocaine/tetracaine cream
was found to be superior in producing
anesthetic effects compared to the placebo in
both studies [1]. Similar results were found in
another double-blinded, randomized, placebo-
controlled study with laser treatment of leg
veins. Significantly less pain was noted with
lidocaine/tetracaine cream use compared to
placebo by subjects and investigators
(P\0.001) [22].
The effectiveness of lidocaine/tetracaine
cream was further evaluated in a double-blind
study of 20 subjects undergoing nonablative
laser treatment [12]. Subjects, investigators, and
independent observers assessed the anesthetic
effects of lidocaine/tetracaine cream compared
to placebo after a 30-min application time [12].
VAS scores were significantly lower in the
treatment sites compared to placebo
(P\0.001) [12]. Investigators also noted
adequate anesthesia in 95 % of treatment sites
compared to 20 % of placebo sites [12].
Lidocaine/tetracaine cream and EMLA cream
were compared in a head-to-head, double-blind
study of 20 patients before ablative CO2 laser
skin resurfacing, a more painful laser procedure
than most [23]. Subjects were randomly
assigned to receive either lidocaine/tetracaine
cream or EMLA cream to the treatment areas.
Subjects, investigators, and independent
assessors assessed the pain relief using the VAS
and other pain scales [23]. Patients who
received lidocaine/tetracaine cream had lower
pain scores compared to those who received
EMLA cream [23]. Ninety-five percent of
lidocaine/tetracaine cream subjects reported
adequate pain relief compared to 20 % of
EMLA cream subjects [23]. The investigators
and independent assessors also observed similar
results [23].
In 2005, two studies were published
evaluating lidocaine/tetracaine cream use with
similar findings. A randomized, double-blind,
placebo-controlled study evaluated lidocaine/
tetracaine cream application for 60 min in 30
subjects undergoing laser-assisted tattoo removal
[24]. Subjects reported significantly lower pain
scores with lidocaine/tetracaine cream use
(P = 0.001) [24]. The investigator evaluations
were similar to subject observations (P\0.001)
[24]. Another randomized, double-blind,
placebo-controlled parallel study evaluated
lidocaine/tetracaine cream use for 20 min in 80
subjects receiving pulsed dye laser therapy [25].
Subject pain scores were significantly lower in
the lidocaine/tetracaine cream group (P = 0.008)
[25]. The investigator evaluations also favored
lidocaine/tetracaine cream over placebo (all
P values\0.0069) [25].
Most recently, lidocaine/tetracaine cream
was studied in a phase 2, double-blind,
placebo-controlled study in patients
undergoing laser-assisted hair removal [26].
The phase 2 study evaluated 60 subjects with
doses dependening on treatment surface area.
Subjects were randomized to 30-, 45-, or 60-min
treatment groups with concurrent applications
of lidocaine/tetracaine cream and placebo to
treatment area halves [26]. Subjects,
investigators, and independent observers rated
the pain experienced by the subjects after the
procedure [26]. Lidocaine/tetracaine cream
subject pain evaluations were significantly
lower than those of placebo (P\0.001)[26].
Subjects also reported significantly greater
adequate anesthesia with lidocaine/tetracaine
cream compared to placebo (P\0.001) [26].
The investigators and observers reported similar
evaluations for both of these end points [26].
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A summary of lidocaine/tetracaine cream
studies for dermatologic laser procedures is
presented in Table 1 [1, 2, 12, 22–26].
Safety and Tolerability
There are no set standard guidelines for the use
and safety of compounded mixtures, so the
need for a safe treatment profile is crucial [5, 7,
11]. This is particularly true given the reports of
systemic toxicity and four deaths associated
with other topical anesthetic preparations,
especially when used under occlusion with
laser procedures [7, 27, 28]. Topical
anesthetics are generally regarded as safe, but
compounding in nonstandard doses and
excessive exposure can result in dangerous
results [29]. While the risk of systemic
absorption of topical lidocaine is relatively
low, side effects indicating systemic effect
include dizziness, drowsiness, muscle twitches,
seizures, respiratory distress, loss of
consciousness, and cardiac arrest [6]. Allergic
reactions to local anesthetics are more
common with use of the ester type of
anesthetics [30]. There is an additional
warning for use of local anesthetics, including
lidocaine/tetracaine cream, in individuals with
hepatic dysfunction. The half-life of lidocaine
may be increased in these subjects and those
with cardiac dysfunction [17]. In addition,
epinephrine, which is typically added to
lidocaine preparations to extend the
anesthetic effect, is associated with skin
blanching [31, 32].
The typical adverse effects, including edema,
erythema, and blanching, seen with EMLA
cream are transient and usually localized to
the application site [11]. EMLA has also been
associated with methemoglobinemia, a serious
condition caused by oxidation of the iron in red
blood cells preventing hemoglobin from
transporting oxygen. This condition is a
recognized complication of other local
anesthetics, particularly prilocaine [11, 33, 34].
Lidocaine/tetracaine cream is FDA-approved
for adults 18 years and older, and has a well-
tolerated safety profile with mild and transient
side effects when used as recommended [3, 11,
30, 35]. Its most common side effects are
transient skin erythema, skin discoloration,
and edema [2, 3, 11]. At least one case of
urticaria has been reported [30]. Although there
have been no reports of methemoglobinemia
with lidocaine/tetracaine cream use, it is listed
as a warning for local anesthetics, including
tetracaine. In addition, subjects with a known
history of sensitivity to lidocaine, tetracaine,
local anesthetics (amide or ester), and para-
aminobenzoic acid (PABA) should not use
lidocaine/tetracaine cream [17].
The systemic levels of lidocaine and
tetracaine in the plasma of 36 subjects that
used lidocaine/tetracaine cream were evaluated
to determine the extent of systemic absorption.
The pharmacokinetic profile of lidocaine and
tetracaine after a single application of lidocaine/
tetracaine cream was assessed in one open label,
randomized, parallel group design [35]. Subjects
were randomized to one of the three groups;
30-, 60-, and 90-min application times. The
plasma samples were obtained at baseline, every
30 min for 3.5 h, and 5 and 7 h after the initial
application [35]. The systemic concentrations
for both lidocaine and tetracaine in all the
samples were below the lower limits of
quantification for the assays used (lidocaine
100 ng/mL, tetracaine 5 ng/mL) [35]. As a result,
the pharmacokinetic parameters beyond
maximum concentration (Cmax) could not be
determined [35]. Central nervous system
toxicity for lidocaine is typically observed at
5,000 ng/mL; a small number of subjects may
show signs of toxicity at 1,000 ng/mL [17].
Pain Ther (2013) 2:11–19 17
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Tetracaine levels of toxicity are similar to
lidocaine, but at lower levels—the exact
numbers are unclear [17]. The use of co-
administered local anesthetics toxicity levels is
thought to be at least additive [17]. Providers
should make sure that the doses, areas of
application, and duration of application are
consistent with those recommended for the
intended population. The low systemic
exposure and mild adverse event reports
provide lidocaine/tetracaine cream with a
benefit over many other available local topical
anesthetics [11].
CONCLUSION
The need for continued improvement in patient
pain management is growing as the number
and types of outpatient dermatology procedures
increase. Lidocaine/tetracaine cream offers the
advantages typical of many topical anesthetics,
including fast, effective pain reduction, limited
systemic effects, and elimination of needles. In
addition, lidocaine/tetracaine cream has several
additional attributes that are unique to its
formulation, including ease of application and
removal, self-occluding formulation, and ability
for use in skin folds.
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